Table 5.

In vitro antibacterial activity of imipenem (IPM), ceftazidime (CAZ) and cefepime (FEP), in the absence and presence of 32 µg/mL of tested compound, on clinical isolates producing several types of clinically relevant β-lactamases.

Compound (32 μg/mL)	MIC (μg/mL)
	K. pneumonia SI-109 $\left({bl{a}_{\text{KPC}-\text{3}}}^{+}\right)$	K. pneumonia SI-001G $\left({bl{a}_{\text{VIM}-\text{1}}}^{+}\right)$	E. Coli SI-002M $\left({bl{a}_{\text{NDM}-\text{1}}}^{+}\right)$	E. Coli SI-2602P $\left({bl{a}_{\text{CMY}-\text{2}}}^{+}\right)$
	IPM	IPM	IPM	CAZ	FEP
None	16	8	16	128	2
10	16	8	16	128	2
20	16	8	16	128	2
24	16	8	16	128	2
31	16	8	16	128	2
32	16	8	16	128	2
40	16	4	1	128	1
46	16	8	16	128	2
52	16	8	8	128	1
55	16	8	16	128	2
59	16	8	16	128	1